Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bintrafusp alfa plus doxorubicin in advanced soft-tissue sarcoma
2020-005703-39Phase 2Active
- Sponsor
- Institut Bergonié
- Start
- Jun 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of bintrafusp alfa and doxorubicin in soft tissue sarcoma (STS) (2 cohorts), sponsored by Institut Bergonié. Primary endpoint: 6-month progression-free rate. Started Jun 2021; status: active.
02
Drugs
bintrafusp alfadoxorubicin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2020-005703-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005703-39.